Abstract
Currently, topical glucocorticosteroids are the most frequently used drugs in dermatologic practice. Over the years, research has focused on strategies to optimize potency and, in particular, the anti-inflammatory and immunosuppressive capacity of these drugs, while minimizing adverse effects. However, ‘ideal’ topical corticosteroids have not yet been synthesized. They should be able to permeate the stratum corneum and reach adequate concentrations in the skin without reaching high serum concentrations. Such characteristics can be obtained by increasing the natural lipophilicity of corticosteroids, e.g. by esterification. In the past, many structural modifications have been made to improve the efficacy of topical corticosteroids to produce drugs with greater potency, although this has often been associated with a higher likelihood of adverse effects. Betamethasone dipropionate and clobetasol propionate, known as fifth-generation corticosteroids, are a typical example of potent molecules that can control specific dermatoses very rapidly, but which are associated with a high risk of topical and systemic adverse effects.
Recently, steroid components have been synthesized that aim to have adequate anti-inflammatory effects and minimal adverse effects. The newest topical corticosteroids used for the treatment of different dermatoses and allergic reactions of the respiratory tract (in particular asthma) are budesonide, mometasone furoate, prednicarbate, the di-esters 17,21-hydrocortisone aceponate and hydrocortisone-17-butyrate-21-propionate, methylprednisolone aceponate, alclometasone dipropionate, and carbothioates such as fluticasone propionate. These new topical corticosteroids are evaluated in the current review, which compares the risk/benefit ratio of each molecule with established agents. The new molecules, compared with the well known and established corticosteroids, generally have a higher anti-inflammatory effect, good compliance among patients (only a once-daily application is needed), rarely induce cross-sensitivity reactions and have weak atrophogenicity.
Similar content being viewed by others
References
Goldman L., Thomson R.G., Trice E.R. Cortisone acetate in skin disease: local effect in skin from topical applicants and local injections. AMA Arch Dermatol Syph 1952; 19: 101–2
Murray J.R. The history of corticosteroids. Acta Derm Venereol 1989; 69 Suppl. 151: 4–6
Ballare P.L., Baxter J.D., Higgins S.J., et al. General presence of glucocorticoid receptors in mammalian tissue. Endocrinology 1974; 94: 998–1002
Epstein E.H., Bonifas J.M. Glucocorticoid receptors of the human epidermis. J Invest Dermatol 1982; 78: 144–6
De Bosscher K., Vanden Berghe W., Haegeman G. Mechanism of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109 (1): 16–22
Biola A., Pallardy M. Mode of action of glucocorticoids. Presse Med 2000; 29 (4): 215–23
Blackwell G.J., Carnuccio R., DiRosa M., et al. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticosteroids. Nature 1980; 287: 147–9
Hirata F., Schiffmann E., Venkatasubamanian K., et al. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticosteroids. Proc Natl Acad Sci USA 1980; 77: 2533–6
Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol 1989; 69 Suppl. 151: 7–10
Prillo J.E., Fauci A.S. Mechanisms of glucocorticoid action on immune processes. Ann Rev Pharmacol Toxicol 1979; 19: 179–201
Vernon-Roberts B. The effects of steroid hormones on macrophage activity. Int Rev Cytol 1969; 25: 131–59
Thompson J., van Furth R. The effect of glucocorticosteroids on the kinetics of mononuclear phagocytes. J Exp Med 1970; 131: 429–42
Newton R. Molecular mechanism of glucocorticoid action: what is important? Thorax 2000; 55: 603–13
Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000; 18: 309–45
Marks R., Williams K. The action of topical corticosteroids on the epidermal cell cycle. In: Wilson J.H., Marks P.A., editors. Mechanisms of topical corticosteroid activity. Edinburgh: Churchill Livingstone, 1976: 39–45
Munro D., Pringle W.M. Psoriasis: its response to dithranol and clobetasol propionate; a comparative study. In: Wilson J.H., Marks P.A., editors. Mechanisms of topical corticosteroid activity. Edinburgh: Churchill Livingstone, 1976: 88–100
Altura B.M. Role of glucocorticosteroids in local regulation of blood flow. Am J Physiol 1966; 211: 1393–7
Juhlin L., Michaelsson G. Cutaneous vascular reactions to prostaglandins in healthy subjects and in patients with urticaria and atopic dermatitis. Acta Derm Venereol 1969; 49: 251–61
Lavker R., Scheckter N. Cutaneous mast cell depletion results from topical corticosteroid usage. J Immunol 1985; 135: 2368–73
Scoggins R.B., Kliman B. Relative potency of percutaneously absorbed corticosteroids in the suppression of pituitary-adrenal function. J Invest Dermatol 1965; 45: 347–55
Ortega E., Burdick K.H., Segre E.J. Adrenal suppression by clobetasol propionate. Lancet 1975; I (7917): 1200
Gomez E.L., Frost P. Induction of glycosuria and hyperglycaemia by topical corticosteroid therapy. Arch Dermatol 1976; 112: 1559–62
Staughton R.C.D., August P.J. Cushing’s syndrome and pituitary-adrenal suppression due to clobetasol propionate. BMJ 1975; 2: 419–21
Fisher D.A. Adverse effects of topical corticosteroid use. West J Med 1995; 162: 123–6
Litt J.Z. Steroid-induced rosacea. Am Fam Phys 1993; 48: 67–71
Sneddon I.B. Perioral dermatitis. Br J Dermatol 1972; 87: 430–4
Hurwitz R.N. Steroid acne. J Am Acad Dermatol 1989; 21: 1179–81
Rook A., Dawber R. Hypertrichosis. In: Rook A., Dawber R., editors. Diseases of the hair and scalp. London: Blackwell Science, 1982: 256
Renfo L., Snow J.S. Ocular effects and systemic steroids. Dermatol Clin 1992; 10 Suppl. 3: 505–12.
Solomon B.A., Glass A.T., Rabbin P.E. Tinea incognita and over-the-counter potent topical corticosteroids. Cutis 1996; 58 Suppl. 4: 295–6.
Anigbogu A.N., Maibach H.I. Topical corticosteroid therapy. In: Millikan L.E., editor. Drug therapy in dermatology. New York: Marcel Dekker Inc., 2000: 1–29
English J.S. Corticosteroid-induced contact dermatitis: a pragmatic approach. Clin Exp Dermatol 2000; 25 (4): 261–4
Baumann L., Kerdel F. Topical glucocorticosteroids. In: Fitzpatrick T., editor. Dermatology in general medicine. 5th ed. New York: McGraw Hill, 1999: 2713–7
Thomson K.F., Wilkinson S.M., Powell S., et al. The prevalence of corticosteroid allergy in two U.K. centres: prescribing implications. Br J Dermatol 1999; 141: 863–6
Wilkinson S.M., Jones M.F. Corticosteroid usage and binding to arginine: determinants of corticosteroid hypersensitivity. Br J Dermatol 1996; 135: 225–30
Bircher A.J., Bigliardi P., Zaugg T., et al. Delayed generalized allergic reactions to corticosteroids. Dermatology 2000; 200: 349–51
Ohi T. Contact dermatitis due to topical steroids with a conceivable cross-reaction between topical steroid preparations. J Dermatol 1996; 23: 200–8
McKenna D.B., Murphy G.M. Contact allergy to topical corticosteroids and systemic allergy to prednisolone. Contact Dermatitis 1998; 38: 121–2
Goossens A., Matura M., Degreef H. Reactions to corticosteroids: some new aspects regarding cross-sensitivity. Cutis 2000; 65: 43–5
Coopman S., Degreef H., Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol 1989; 121: 27–34
Corazza M., Mantovani L., Maranini C., et al. Contact sensitization to corticosteroids: increased risk in long-term dermatoses. Eur J Dermatol 2000; 10 (7): 533–55
Drake L., Dinehart S., Farmer E., et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol 1996; 35 (4): 615–9
Isaksson M., Brandao F.M., Bruze M., et al. Recommendation to include budesonide and tixocortol pivalate in the European standard series, ESCD and EECDRG: European Society of Contact Dermatitis. Contact Dermatitis 2000; 43 (1): 41–2
Du Vivier A., Stoughton R.B. Acute tolerance to effects of topical glucocorticosteroids. Br J Dermatol 1976; 94: 25–32
Clement M., Phillips H., Du Vivier A. Is steroid tachyphylaxis preventable? Clin Exp Dermatol 1985; 10: 22–9
Franz T.J., Parsell D.A., Halualani R.M., et al. Betamethasone valerate foam 0.12 %: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628–32
Schmid M.H., Korting H.C. Liposomes: a drug carrier system for topical treatment in dermatology. Crit Rev Ther Drug Carrier Syst 1994; 11 (2–3): 97–118
Giannotti B., Pimpinelli N. Topical corticosteroids: which drug and when? Drugs 1992; 44 (1): 65–71
Long C.C., Mills C.M., Finlay A.Y. A practical guide to topical therapy in children. Br J Dermatol 1998; 138: 293–6
Lagos B.R., Maibach A.I. Frequency of application of topical corticosteroids: an overview. Br J Dermatol 1998; 139: 763–6
Paul M.A., Krowchuk D.P., Hitchcock M.G., et al. Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. Pediatr Dermatol 1996; 13 (6): 501–6
Van der Vleuten C.J., Van Vlijmen I.M., De Jong E.M., et al. Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17 propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. Arch Dermatol Res 1999; 291 (7–8): 390–5
Mori M., Pimpinelli N., Giannotti B. Topical corticosteroids and unwanted local effects: improving the benefit/risk ratio. Drug Saf 1994; 10 (5): 406–12
Spencer C.M., Wiseman L.R. Topical fluticasone propionate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs 1997; 7 (4): 318–34
Quintiliani R. Hypersensitivity and adverse reactions associated with the use of newer intranasal corticosteroids for allergic rhinitis. Curr Ther Res Clin Exp 1996; 57: 478–88
Wilkinson S.M., Beck M.H. Fluticasone propionate and mometasone furoate have a low risk of contact sensitisation. Contact Dermatitis 1996; 34: 365–6
Corazza M., Virgili A. Allergic contact dermatitis from a-methylprednisolone aceponate and budesonide. Contact Dermatitis 1998; 38: 356–7
Goh C.L., Lim J.T., Leow Y.H., et al. The therapeutic efficacy of mometasone furoate cream 0.1 % applied once daily vs clobetasol propionate cream 0.05 % applied twice daily in chronic eczema. Singapore Med J 1999; 40 (5): 341–4
Kelly J.W., Cains G.D., Rallings M., et al. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Aust J Dermatol 1991; 32 (2): 85–91
Vernon H.J., Lane A.T., Weston W. Comparison of mometasone furoate 0.1 % cream and hydrocortisone 1.0 % cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991; 24 (4): 603–7
Haapasaari K.M., Resteli J., Karvonen J., et al. Effect of hydrocortisone, methylprednisolone aceponate and mometasone furoate on collage synthesis in human skin in vivo. Skin Pharmacol 1997; 10 (5–6): 261–4
Prakash A., Benfield P. Topical mometasone: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998; 55 (1): 145–63
Lange K., Kleuser B., Gysler A., et al. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticosteroids. Skin Pharmacol Appl Skin Physiol 2000; 13 (2): 93–103
Lange K., Gysler A., Bader M., et al. Prednicarbate versus conventional topical glucocorticosteroids: pharmacodynamic characterization in vitro. Pharm Res 1997; 14 (12): 1744–9
Kecskés A., Jahn P., Matthes H., et al. Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers. J Am Acad Dermatol 1993; 28 (5): 789–92
Kecskés A., Jahn P., Lange L. Local tolerability of topically applied methylprednisolone aceponate. J Am Acad Dermatol 1993; 28 (5): 786–8
Günther C., Kecskes A., Staks T., et al. Percutaneous absorption of methylprednisolone aceponate following topical application of Advantan® lotion on intact, inflamed and stripped skin of male volunteers. Skin Pharmacol Appl Skin Physiol 1998; 11: 35–42
Hoffmann K., Auer T., Stucker M., et al. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol 1998; 10 (2): 137–42
Kecskés A., Heger-Mahn D., Kuhlmann R.K., et al. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. J Am Acad Dermatol 1993; 29 (4): 576–80
Balato N., Patruno C., Lembo G., et al. Contact sensitisation to 6 alpha-methylprednisolone aceponate. Am J Contact Dermat 1997; 8 (1): 24–5
Meingassner J.G., Grassberger M., Fahrngruber H., et al. A novel anti-inflammatory drug, Pimecrolimus (SDZ-ASM-981), for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568–76
Van Leent E.J.M., Gräber M., Thurston M., et al. Effectiveness of the ascomycin macrolatum SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805–9
Grassberger M., Baumruker T., Hiestand P., et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264–73
Neckermann G., Bavandi A., Meingassner J.G. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 2000; 142: 669–79
Ruzicka T., Assmann T., Homey B. Tacrolimus: the drug of the turn of the millennium? Arch Dermatol 1999; 135: 574–80
Assmann T., Homey B., Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 2000; 47 (2–3): 203–13
Leung D.Y.M., Soter N.A. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001; 44 Suppl. 1: S1–12
Bekersky I., Fitzsimmons W., Tanase A., et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44 Suppl. 1: S17–27
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brazzini, B., Pimpinelli, N. New and Established Topical Corticosteroids in Dermatology. Am J Clin Dermatol 3, 47–58 (2002). https://doi.org/10.2165/00128071-200203010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200203010-00005